Grants and Support

IMI Grants

The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry. IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.

IMI is the world's biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Through the IMI2 programme, a €3.3 billion budget for the period 2014-2020 is available.

The goal of IMI, particularly in its second phase (IMI2, 2014-2020) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. The projects will provide Europeans, including the increasing numbers of older people, with more efficient and effective medicines and treatments. Greater coordination across industry sectors will result in more reliable and faster clinical trials, and better regulation. Research and innovation efforts will also open new commercial possibilities based on new services and products. The research, industry and societal sectors involved in IMI2 will benefit from the cooperation and knowledge sharing which take place in these projects.

(source: IMI website)

LUMC researchers participate(d) in the following IMI projects:


EU IMI Grant - ABIRISK
EU IMI Grant - APPROACH
EU IMI Grant - BTCURE
EU IMI Grant - COMBACTE-CDI
EU IMI Grant - DIRECT
EU IMI Grant - ELF
EU IMI Grant - INNODIA
EU IMI Grant - Open PHACTS
EU IMI Grant - PERISCOPE
EU IMI Grant - PRISM
EU IMI Grant - RHAPSODY
EU IMI Grant - ROADMAP
EU IMI Grant - RTCure
EU IMI Grant - VSV-EBOPLUS
EU IMI Grant - VSV-EBOVAC
EU IMI Grant - ZAPI